Rabies Antiserum is a complex biological agent comprised of purified antibody fractions obtained from the blood plasma of animals hyperimmunized with inactivated rabies virus. It provides passive, short-term post-exposure prophylaxais in rabies infected or high risk of infection cases until the active immunity develops in response to rabies vaccine. Rabies Antiserum confers immediate protection against rabies virus infection and buys critical time for post exposure prophylaxis.
Market key trends
One of the key trends in the rabies antiserum market is the rising R&D investments by manufacturers for the development of new and advanced antiserum products. For instance, manufacturers are focusing on developing humanized monoclonal antibodies derived antisera as an alternative to conventional equine or other animal-derived immunoglobulin preparations. Humanized antibodies-based antisera offer advantages such as less adverse reactions, precisely defined composition, and standardized doses.
The global Rabies Antiserum Market Share is estimated to be valued at US$ 1.24 Bn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Strength: Rabies Antiserum is an effective treatment for rabies exposure. It acts by providing antibodies against rabies virus and prevents the development of clinical disease if given promptly after exposure.
Weakness: Rabies Antiserum is derived from animals and carries a small risk of allergic reactions in some individuals. The production process also makes it relatively expensive compared to vaccination.
Opportunity: Increasing incidence of dog bites in developing regions of Asia and Africa is expected to boost the demand for Rabies Antiserum for post-exposure prophylaxis. Favorable government support for animal bite management programs also opens growth opportunities.
Threats: Development of alternative post-exposure biologics and widespread vaccination efforts can reduce the target population for Rabies Antiserum over the long run. Stringent regulations associated with biological production also pose challenges.
The global Rabies Antiserum market is expected to witness high growth, exhibiting CAGR of 3.3% over the forecast period, due to increasing incidence of animal bites worldwide. Asia Pacific region currently dominates the market due to large patient pools in countries like India and China.
Regional analysis: Asia Pacific is expected to remain the dominant as well as the fastest growing regional market for Rabies Antiserum during the forecast period. This is attributed to large populations and increasing cases of dog bites in developing countries such as India and China. North America and Europe are also significant markets owing to the growing adoption of pet animals.
Key players operating in the Rabies Antiserum market are CSL Behring, Sanofi Pasteur, Grifols S.A., Bharat Serum and Vaccines Ltd., Novartis AG, Kedrion Biopharma Inc., Biogenesis Bago SA, MassBiologics, Serum Institute of India Ltd., Green Cross Corp., Haffkine Bio-Pharmaceutical Corporation Ltd., Shanghai Institute of Biological Products Co. Ltd., CNBG (China National Biotec Group) Co. Ltd., Harbin Pharmaceutical Group Co. Ltd., Beijing Tiantan Biological Products Co. Ltd.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it